Lilly’s Zepbound (aka tirzepatide) Lands FDA Approval for Weight Loss
CardiacWire
NOVEMBER 12, 2023
The US obesity management arena gained a major new competitor last week with the FDA approval of Eli Lilly’s Zepbound, giving obese and overweight patients in the US a second (on-label) option beyond Novo Nordisk’s Wegovy. Zepbound is Lilly’s new obesity-targeted brand for tirzepatide, which has been available to US diabetic patients under its Mounjaro brand since May 2022 Although often referred to as a GLP-1, tirzepatide uniquely activates both GIP (affects adipose tissue regulation and storag
Let's personalize your content